



3000 Sand Hill Road Building 3, Suite 290
Menlo Park, CA 94025
PHONE (650) 854-7236 FAX (650) 854-7365
WWW.MDV.COM

FOR RELEASE

Sue Siegel Joins MDV with Focus on Life Science Investing

Brings Valuable Industry Experience Developing New Markets

MENLO PARK, CA, March 29, 2007 — MDV-Mohr Davidow Ventures, (www.mdv.com), a leading Silicon Valley venture capital firm, today announced the addition of Sue Siegel, a veteran life sciences executive, as a partner with the firm. She will join MDV's life sciences team and invest in cross-discipline companies developing and commercializing enabling technologies that will improve biopharmaceutical research and development and transform the practice of medicine.

"Sue is a great addition to our team," said MDV Partner Bill Ericson. "She has demonstrated exceptional company-building and leadership skills, all of which will be attractive to first-time and repeat life science entrepreneurs. She has experienced firsthand what's required to successfully bring to market enabling technologies that accelerate the healthcare industry along the path to personalized medicine."

During the past 20+ years Siegel has worked in the life sciences industry where she led businesses that commercialized key enabling technologies in biomedical research and healthcare.

"I'm pleased to be part of the MDV team," Siegel said. "It is a venture firm that is taking a leadership position in making personalized medicine more than a catch phrase. They've demonstrated their commitment by investing in promising life sciences startups looking to accelerate drug discovery, diagnostics and therapies that will more precisely help diagnose and treat diseases."

Prior to joining MDV, Siegel was President and Director of Affymetrix, Inc., a company that pioneered GeneChip® technology, propelling the expansion of the genomics field and the opportunity for personalized medicine. Formerly, Siegel was at Amersham International (now GE Healthcare) where her last role was President of the Hoefer-Pharmacia Biotech business. Previously, she built her experience in biotechnology and healthcare at E. I. DuPont & Co., Eastman Kodak Co., and Bio-Rad Laboratories.

Siegel is also a member of the board of directors of Pacific Biosciences, an MDV company. She is a member of the Presidents' Circle of the National Academies, serves as an advisor to the Institute of Medicine, and is a board member of The Tech Museum of Innovation, Silicon Valley. She is a member of the Advisory Council of The J. David Gladstone Institutes in San Francisco, a world leading biomedical research organization.

MDV has funded entrepreneurial life sciences teams that bring a blend of backgrounds – from molecular biology to computer science to physics to chemistry – and are developing companies that apply a powerful multi-disciplinary approach from inception. The firm is specifically focused on life sciences companies whose products are on track to make it to market inside of three to five years. Siegel joins Bill Ericson, Michael Goldberg, Rowan Chapman, Ph.D., and Vance Vanier, M.D., on the MDV life sciences investing team.



MOHR DAVIDOW VENTURES

3000 Sand Hill Road Building 3, Suite 290
Menlo Park, CA 94025

PHONE (650) 854-7236 FAX (650) 854-7365
WWW.MDV.COM

About MDV-Mohr Davidow Ventures

MDV is a leading early stage Silicon Valley-based venture capital firm that for nearly 25 years has identified, mentored and developed entrepreneurs and young companies redefining business technology and medicine. The firm invests around three major business and science concerns: Powering the Planet; Personalizing Medicine; and Driving the Digital World. The firm partners with entrepreneurs who have deep expertise in energy and materials, life sciences, and the Internet. MDV's team engages very early in the life of a company to impact its long-term success. Category-leading companies funded by MDV include Agile, Brocade, Energy Innovations, Epigram (BRCM), FormFactor, Ipsilon Networks (NOK), Kalpana (CSCO), Nanosolar, NeuroMolecular Pharmaceuticals, ONI Systems (CIEN), Pacific Biosciences, ParAllele (AFFX), Pivotal Technologies (BRCM), Proofpoint, Revenue Science, and Shutterfly. MDV has \$1.4 billion dollars under management. For more information, please visit www.mdv.com.

Media Contact: Pamela Mahoney 650-854-7236 - pmahoney@mdv.com